Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07483294 · ClinicalTrials.gov registry record
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
A clinical trial of Psychosis; Acute, sponsored by Northwell Health.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07483294: Recruiting study of Psychosis; Acute, sponsored by Northwell Health.
NCT07483294 is a study of Psychosis; Acute that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07483294, a study of Psychosis; Acute, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with either risperidone or aripiprazole for 12 weeks, with dosage and titration followed by standard clinical care. A comprehensive clinical and neuroimaging assessments will be performed before and after treatment.
Primary Outcome
To investigate the performance of cerebellar-cortical functional connectivity in prediction of antipsychotic response
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (1)
New York
- Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2030-06-01 |
What NCT07483294 shows while recruiting
NCT07483294 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Psychosis; Acute appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT07483294 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07483294 about?
NCT07483294 is a clinical study titled "Cerebellum-based Imaging Neural Markers for Antipsychotic Response". This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with ...
What is the current status of trial NCT07483294?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-11-01. Estimated completion is 2030-06-01.
What conditions does trial NCT07483294 study?
This clinical trial studies the following conditions: Psychosis; Acute.
What interventions are being tested in trial NCT07483294?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT07483294?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07483294 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI